Muhammad UmairMushtaqMD

PubMed

• 6 citations
  Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
  Nausheen Ahmed, William Wesson, Muhammad Umair Mushtaq, David L Porter, Sunita D Nasta
  Transplantation and Cellular Therapy. 2023-07-01
• 2 citations
  Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation.
  Joe S Al-Ramahi, Moazzam Shahzad, Andrea Nguyen, Kevin Li, Muhammad Kashif Amin
  Bone Marrow Transplantation. 2024-01-01
• 32 citations
  Knowledge, attitudes and practices regarding tuberculosis in two districts of Punjab, Pakistan.
  Muhammad Umair Mushtaq, Muhammad Ashraf Majrooh, W Ahmad, Muhammad Rizwan, M Q Luqman
  The International Journal of Tuberculosis and Lung Disease. 2010-03-01

Abstracts/Posters

• The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023
  Atallah R, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S375-S376, 2/2024
• The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally
  Atallah R, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S373-S374, 2/2024
• The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma
  Khaliq A, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S208, 2/2024
• Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure
  Lutfi F, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S229, 2/2024
• BCMA Re-Emergence: Can It Serve As a Prognostic Biomarker in Multiple Myeloma after CAR-T?
  Rashid A, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S194-S195, 2/2024
• Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy
  Soomro MA, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S373, 2/2024
• Chimeric Antigen Receptor T-Cell (CAR-T) Access Among Rural and Health Professional Shortage Area (HPSA) Populations in the Midwest
  Tabak C, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S323, 2/2024
• VD-PACE As Salvage and Bridging Therapy to Transplant and Cellular Therapy in Triple Class Relapsed/Refractory Multiple Myeloma
  Venkatesh P, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S389-S390, 2/2024
• A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients
  Wesson W, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S207-S208, 2/2024
• Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
  Amin MK … Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S241-42, 2/2024
• Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Ce...
  Shahzad M … Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S172, 2/2024
• Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myelo...
  Shah N, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S225-S226, 2/2024
• BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma
  Rashid A, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6801, 12/2023
• Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma
  Wesson W, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6914, 12/2023
• Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians
  Atallah R, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6678, 12/2023
• Vdpace As Salvage Therapy in Triple Class Relapse/Refractory Multiple Myeloma
  Venkatesh P, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6694, 12/2023
• Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure
  Lutfi F, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6916, 12/2023
• Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy
  Soomro MA, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6900, 12/2023
• Outcomes after Bone Marrow Versus Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation
  Al-Ramahi J … Mushtaq MU, Blood. 2023; 142 (S1): 7028, 12/2023
• The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally
  Atallah R, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 3327, 12/2023
• Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics
  Snyder J, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 1985, 12/2023
• Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant
  Mammadzadeh A, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 4727, 12/2023
• The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma
  Khaliq A, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 2344, 12/2023
• Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis
  Amin M … Mushtaq MU, Blood. 2023; 142 (S1): 2242, 12/2023
• Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Ce...
  Shahzad M … Mushtaq MU, Blood. 2023; 142 (S1): 3523, 12/2023
• Join now to see all

Lectures

• Highlights of American Society of Hematology Annual Meeting 2023. University of Kansas Cancer Center ASH Review 
  Kansas City, KS - 1/2024
• Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients. Grand Rounds Speaker at the University of Kansas Me... 
  Kansas City, KS - 4/2022
• Graft failure and graft rejection. American Society of Transplantation & Cellular Therapy Fall Clinical Education Conference (ASTCT CEC) 
  Virtual - 9/2021
• Highlights of American Society of Hematology Annual Meeting 2020. University of Kansas Cancer Center ASH Review 
  Kansas City, KS - 1/2021
• Highlights of American Society of Hematology Annual Meeting 2019. University of Wisconsin Carbone Cancer Center Grand Rounds 
  Madison, WI - 1/2020
• Matrix-based biomarkers for cancer immunotherapy. Guest Speaker at University of Kansas, Kansas City, KS (08/2019), University of Arizona, Tucson, AZ (08/2019), Wake F... 
  8/2019
• Highlights of American Society of Hematology Annual Meeting 2018. University of Wisconsin Carbone Cancer Center Grand Rounds 
  Madison, WI - 2/2019
• Join now to see all